Kazia Therapeutics (NASDAQ: KZIA)

Last close As at 20/12/2024

1.32

0.04 (3.13%)

Market capitalisation

22m

Kazia Therapeutics is an ASX- and NASDAQ-listed biotechnology company. It is developing the PI3K/mTOR inhibitor GDC-0084 for brain cancer and Cantrixil for ovarian cancer. GDC-0084 was in-licensed from Genentech in 2016.

Latest Insights

View More

Thematics

thematic

Borussia Dortmund – executive interviews

thematic

UK equities: A generational opportunity?

thematic

Energy & Resources

Renewable energy developers – Creating value for investors

thematic

Healthcare

Healthcare-focused trusts: A sector on the mend

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free